Fig. 3From: Using second harmonic generation to predict patient outcome in solid tumorsProgression-free survival as a function of F/B in ER+ recurrent breast cancer patients treated with tamoxifen. The patients are divided in four equal quarters (Q1-Q4) based on their F/B tumor level. Patients at risk at various time points are indicatedBack to article page